Citigroup’s COSCIENS Biopharma Inc. Common Stock CSCI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q1
Sell
-902
Closed -$2.42K 6043
2024
Q4
$2.42K Buy
+902
New +$2.94K ﹤0.01% 5535
2024
Q3
Sell
-15
Closed -$67 5826
2024
Q2
$67 Buy
+15
New +$114 ﹤0.01% 5466
2022
Q3
Sell
-39
Closed -$1K 6406
2022
Q2
$1K Buy
+39
New +$976 ﹤0.01% 6115
2021
Q3
Sell
-10
Closed -$1K 6370
2021
Q2
$1K Hold
10
﹤0.01% 6065
2021
Q1
$1K Hold
10
﹤0.01% 6124
2020
Q4
$0 Hold
10
﹤0.01% 7668
2020
Q3
$0 Hold
10
﹤0.01% 7635
2020
Q2
$1K Hold
10
﹤0.01% 7480
2020
Q1
$1K Hold
10
﹤0.01% 7525
2019
Q4
$1K Hold
10
﹤0.01% 7623
2019
Q3
$1K Hold
10
﹤0.01% 7640
2019
Q2
$3K Hold
10
﹤0.01% 7581
2019
Q1
$5K Hold
10
﹤0.01% 7430
2018
Q4
$3K Hold
10
﹤0.01% 7474
2018
Q3
$2K Hold
10
﹤0.01% 7621
2018
Q2
$2K Hold
10
﹤0.01% 7480
2018
Q1
$1K Hold
10
﹤0.01% 7476
2017
Q4
$2K Buy
+10
New +$2.08K ﹤0.01% 7407
2016
Q1
Hold
0
7807
2015
Q4
Hold
0
7910
2015
Q1
Sell
-1
Closed -$5K 7474
2014
Q4
$5K Buy
+1
New +$8.4K ﹤0.01% 6683
2014
Q2
Sell
-1
Closed -$8K 7342
2014
Q1
$8K Buy
+1
New +$12.9K ﹤0.01% 6442
2013
Q4
Hold
0
7181
2013
Q3
Hold
0
7023
2013
Q2
Hold
0
6801

Other funds holding CSCI

Citigroup's CSCI Position: Q1 2025 in Review

Citigroup sold out of COSCIENS Biopharma Inc. Common Stock (CSCI) in Q1 2025, closing a stake of 902 shares — an estimated $2.42K sold.

Citigroup first reported a position in CSCI in Q1 2014 and held it in 20 quarters. The position peaked at $8K in Q1 2014. 15 funds tracked by Wall St. Rank hold CSCI as of Q1 2025.

  • Citigroup reported no remaining COSCIENS Biopharma Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Citigroup sold 902 COSCIENS Biopharma Inc. Common Stock shares in Q1 2025, an estimated $2.42K.
  • Citigroup first reported a position in COSCIENS Biopharma Inc. Common Stock in Q1 2014 and held it in 20 quarters.
  • Citigroup's COSCIENS Biopharma Inc. Common Stock position peaked at $8K in Q1 2014.
  • 15 funds tracked by Wall St. Rank held COSCIENS Biopharma Inc. Common Stock as of Q1 2025.

Based on Citigroup's 13F filing for Q1 2025, filed 12 May 2025.